rs201007090 — F11 Trp519Stop

F11 Trp519Stop — A Coagulation Off-Switch with a Hidden Fuse

Every time blood vessels are injured, a cascade of proteins amplifies the initial clotting signal to rapidly seal the wound. Factor XI¹¹ Factor XI
Coagulation factor XI (FXI) is a serine protease that amplifies thrombin generation in the contact activation phase of coagulation. It circulates as a dimer in plasma and is activated by factor XIIa or thrombin on activated platelet surfaces sits near the middle of this cascade, acting as an amplifier that sustains thrombin generation after an initial clot forms. The rs201007090 variant — a single G-to-A substitution at codon 519 of the F11 gene — introduces a premature stop signal (Trp519Ter), truncating the Factor XI protein and producing little or no functional enzyme. The result is factor XI deficiency²² factor XI deficiency
Also called hemophilia C or Rosenthal disease, first described in the 1950s in families experiencing excessive bleeding with surgery and dental procedures, a mild-to-moderate inherited bleeding disorder.

The Mechanism

The F11 gene encodes a 607-amino-acid serine protease. The Trp519Ter nonsense mutation — caused by a single G>A transition at nucleotide position c.1556 of the canonical transcript (NM_000128.4) — converts a tryptophan codon (TGG) into a stop codon (TAG) at amino acid position 519. This truncates the catalytic domain, abolishing enzymatic activity. mRNAs carrying premature stop codons are typically degraded by nonsense-mediated decay³³ nonsense-mediated decay
A cellular surveillance pathway that degrades mRNAs with premature stop codons to prevent production of truncated, potentially dominant-negative proteins, so the mutant allele typically produces no protein rather than a truncated product.

Inheritance is autosomal recessive. Heterozygous carriers produce approximately 50% of normal FXI activity — enough for adequate hemostasis in most situations, but potentially insufficient under high-fibrinolysis surgical conditions. Homozygotes produce severely reduced or absent FXI activity, typically below 10 IU/dL, and are at significant risk of postoperative hemorrhage.

A critical clinical peculiarity of FXI deficiency is that FXI activity levels correlate poorly with actual bleeding tendency⁴⁴ FXI activity levels correlate poorly with actual bleeding tendency
Unlike hemophilia A or B, where factor activity predicts bleeding risk reliably, FXI-deficient patients with identical activity levels may have markedly different bleeding histories. Bleeding risk seems to depend partly on the specific mutation, platelet function, von Willebrand factor levels, and the fibrinolytic activity of the tissue being operated. This makes genotyping especially valuable — a molecular diagnosis helps predict surgical risk more reliably than activity measurements alone.

The Evidence

The clinical significance of nonsense mutations in F11 is well established. ClinVar classifies rs201007090 (G>A; Trp519Ter) as Pathogenic⁵⁵ ClinVar classifies rs201007090 (G>A; Trp519Ter) as Pathogenic
RCV000169241, 2-star review status — criteria provided, multiple submitters, no conflicts. Submitters include Fulgent Genetics and ISTH-SSC Genomics in Thrombosis and Hemostasis based on convergent pathogenicity criteria across three independent submitters. The variant is extremely rare globally: the A allele appears at a frequency of approximately 1 in 80,000 alleles (0.0000121) in gnomAD exomes, with higher representation in East Asian populations (approximately 0.00028).

Bleeding in FXI deficiency does not occur spontaneously — it is triggered specifically by trauma and surgery in anatomical sites with high intrinsic fibrinolytic activity⁶⁶ triggered specifically by trauma and surgery in anatomical sites with high intrinsic fibrinolytic activity
These include the urinary tract, oral cavity (tonsils, dental sockets), nasopharynx, and uterus. At these sites, tissue plasminogen activator (tPA) is abundant, so clots dissolve rapidly unless FXI-driven thrombin amplification provides sufficient fibrin crosslinking. By contrast, surgery at low-fibrinolysis sites (joints, muscle, skin) carries minimal bleeding risk even in severe deficiency.

Lewandowska and Connors, 2021⁷⁷ Lewandowska and Connors, 2021
Lewandowska MD, Connors JM. Hematol Oncol Clin North Am 2021;35:1157–1169 — comprehensive management review covering the diagnostic challenges of FXI deficiency, variability in treatment access, and thrombotic risks of FXI concentrate highlight that large volumes of fresh frozen plasma are required to achieve hemostatic FXI levels using FFP alone, and that FXI concentrate — while more concentrated — carries thrombotic risk requiring careful patient selection. Antifibrinolytics (tranexamic acid, epsilon-aminocaproic acid) are preferred for mucosal and dental procedures.

Practical Actions

For carriers of one Trp519Ter allele (heterozygotes), surgical planning is the main clinical priority. FXI activity should be measured preoperatively; procedures at high-fibrinolysis sites (tonsillectomy, urological surgery, dental extractions, uterine surgery) require specific hemostatic cover. Antifibrinolytic therapy (tranexamic acid) is first-line for mucosal and dental procedures. FXI concentrate or fresh frozen plasma is reserved for high-risk surgery. Surgical teams and anesthesiologists must be informed of FXI deficiency status before any procedure.

Homozygotes (AA genotype) have severe deficiency requiring management as for moderate hemophilia at all surgical sites. They should be followed by a specialist hematologist and carry emergency medical documentation.

Interactions

Factor XI deficiency interacts with medications that further suppress coagulation. Anticoagulants (warfarin, heparin, direct oral anticoagulants), antiplatelet agents (aspirin, clopidogrel), and NSAIDs all increase surgical bleeding risk disproportionately in FXI-deficient patients. FXI deficiency also intersects with von Willebrand disease — combined deficiency amplifies mucosal bleeding risk.

Other F11 pathogenic variants — including the Ashkenazi Jewish founder mutations at codons 117 (Glu117Stop; type II) and 283 (Phe283Leu; type III) — cause the same clinical syndrome through different molecular defects in the same gene. The Trp519Ter variant acts through the same premature termination mechanism as the type II mutation, though at a different position in the protein.